Ozempic goes up to 2 mg a week and is approved for adults with type 2 diabetes. Wegovy goes to 2.4 mg, with 7.2 mg as its highest dose, and is approved for weight reduction, for cardiovascular risk in people with obesity or overweight, and for a liver disease.
Because the molecule is the same, the two share a starting dose, a half-life and most warnings. This page sets the labels side by side: the dose ladders on your calendar, what each product did in its own trials, side effects, the prices on November 20, 2026, and what to do with a late dose.
Are Ozempic and Wegovy the same drug?
Yes. Both labels describe semaglutide, a GLP-1 receptor agonist injected once a week, and both are made by Novo Nordisk.1,2 The labels differ in approved uses, doses and forms.
| Ozempic | Wegovy | |
|---|---|---|
| Drug | Semaglutide | Semaglutide |
| Approved for | Blood sugar control, cardiovascular risk and kidney disease, all in adults with type 2 diabetes | Weight reduction; cardiovascular risk in adults with cardiovascular disease and obesity or overweight; MASH, a liver disease, with fibrosis |
| Weekly doses | 0.25, 0.5, 1, 2 mg | 0.25, 0.5, 1, 1.7, 2.4 mg, and 7.2 mg |
| Youngest patients | Adults | Age 12 for weight reduction |
| Other forms | Single-dose syringes of 0.25, 0.5 and 1 mg | A daily tablet, 1.5 to 25 mg; single-dose syringes; a four-dose 2.4 mg pen |
| Half-life | About 1 week | About 1 week |
Current prescribing information for each product.1,2
The Wegovy label says it should not be used together with other products that contain semaglutide, or with any other GLP-1 receptor agonist.2 A person takes one or the other.
What exactly is each approved for?
Ozempic has three approved uses, and each is for adults with type 2 diabetes.1
To improve blood sugar control, alongside diet and exercise. To reduce the risk of major cardiovascular events in those who also have established cardiovascular disease. To reduce the risk of a sustained decline in kidney function, kidney failure and cardiovascular death in those who also have chronic kidney disease.
Wegovy injection also has three, none of which requires diabetes, and each is combined with a reduced-calorie diet and more physical activity.2
To reduce excess body weight and keep it off, in adults and children aged 12 and older with obesity and in adults with overweight and at least one weight-related condition. To reduce the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. To treat noncirrhotic MASH with moderate to advanced liver fibrosis in adults.
A person with type 2 diabetes and obesity fits both labels. The Wegovy label covers that case with one instruction: in patients with diabetes, blood sugar is monitored before starting and during treatment.2
How do the dose ladders differ?
They are the same for the first eight weeks: 0.25 mg for four weeks, then 0.5 mg. After that Ozempic may go to 1 mg and 2 mg if more blood sugar control is needed, while Wegovy continues through 1 mg and 1.7 mg to 2.4 mg.1,2
Log each shot and the app keeps the dates for you.
Open the appThe numbers along the bottom are weeks of treatment. These are the earliest dates each label allows. Ozempic's steps to 1 mg and 2 mg are taken only if more blood sugar control is needed. The prescriber decides each step.
The ladders express two different aims. Ozempic's label names 0.5 mg, 1 mg and 2 mg as maintenance doses and moves up only for blood sugar. Wegovy's label names 2.4 mg as the recommended maintenance dose for weight reduction, with 1.7 mg as an alternative, and allows 7.2 mg for adults who have tolerated 2.4 mg for at least four weeks and need more weight reduction.1,2
The Wegovy trials themselves show how its ladder is used. In the trial that tested both maintenance doses, people were brought to 1.7 mg or 2.4 mg over 12 to 16 weeks and then stayed on that dose for 52 weeks. In the trials of the highest dose, people were brought to 2.4 mg or 7.2 mg over 20 weeks, followed by 52 weeks on it.2
In practice many people on Wegovy stop short of the top. In the label's cardiovascular trial, 76% of those still on treatment after a year were on 2.4 mg, 8% on 1.7 mg and 16% on lower doses.2 In Denmark, 13% of people who filled semaglutide prescriptions for weight had reached 2.4 mg by their fifth prescription.5
The pages on the Ozempic dosing schedule and the Wegovy dosing schedule go through each ladder step by step.
What did each one do in its trials?
There is no trial of Ozempic against Wegovy. Each was tested for its own purpose in its own population: Ozempic in people with type 2 diabetes, where the main result is HbA1c, and Wegovy in people with obesity or overweight, where the main result is body weight.1,2
| Trial in the label | Who | Weight change | Comparison group |
|---|---|---|---|
| Ozempic 0.5 mg, 30 weeks | Type 2 diabetes | −3.8 kg | Placebo: −1.2 kg |
| Ozempic 1 mg, 30 weeks | Type 2 diabetes | −4.7 kg | Placebo: −1.2 kg |
| Ozempic 2 mg, 40 weeks | Type 2 diabetes, on metformin | −6.4 kg | 1 mg: −5.6 kg |
| Wegovy 2.4 mg, 68 weeks | Obesity or overweight | −14.9% | Placebo: −2.4% |
Ozempic prescribing information, section 14; Wegovy prescribing information, Table 8.1,2
In the Wegovy trial of 1,306 people on the drug, 83.5% lost at least 5% of their weight, 66.1% at least 10%, 47.9% at least 15% and 30.2% at least 20%. On placebo the figures were 31.1%, 12%, 4.8% and 1.7%.2
What did Wegovy's dose do in people with type 2 diabetes?
This is the closest the labels come to a like-for-like comparison, because Ozempic was tested only in people with type 2 diabetes. One of the Wegovy trials enrolled 807 adults with type 2 diabetes and obesity or overweight. Over 68 weeks, people on 2.4 mg lost 9.6% of their weight and people on placebo 3.4%.2
| Wegovy 2.4 mg, 68 weeks | Average loss | Lost 5% or more | Lost 10% or more | Lost 15% or more |
|---|---|---|---|---|
| Obesity or overweight with a related condition | 14.9% | 83.5% | 66.1% | 47.9% |
| Placebo in that trial | 2.4% | 31.1% | 12% | 4.8% |
| Type 2 diabetes with obesity or overweight | 9.6% | 67.4% | 44.5% | 25.1% |
| Placebo in that trial | 3.4% | 30.2% | 10.2% | 4.3% |
| With intensive lifestyle therapy | 16% | 84.8% | 73% | 53.4% |
| Placebo in that trial | 5.7% | 47.8% | 27.1% | 13.2% |
Wegovy prescribing information, Table 8.2
So the same 2.4 mg dose gave a smaller loss in the trial of people with diabetes than in the main trial: 9.6% against 14.9%. Set next to the Ozempic trials, also in diabetes, where the average loss was 4% to 6% of body weight over 30 to 40 weeks, the higher dose and the longer treatment still came out ahead, by less than the headline figures suggest.
The third Wegovy trial gave everyone intensive lifestyle therapy. People on Wegovy lost 16%, and people on placebo lost 5.7%, against 2.4% on placebo in the main trial.2
What about blood sugar?
That is what Ozempic was built to treat, and its label reports it dose by dose. Alone, over 30 weeks, HbA1c fell 1.4 points on 0.5 mg and 1.6 points on 1 mg, against 0.1 on placebo, and about seven in ten people finished below 7%. In the trial of the top dose, HbA1c fell 2.1 points on 2 mg and 1.9 points on 1 mg.1
Wegovy is not approved for blood sugar control. Its label tells prescribers to monitor blood sugar in people with diabetes before and during treatment, and lists low blood sugar in people with type 2 diabetes among its common reactions: 6% on Wegovy against 2% on placebo.2
What was done alongside the drug in the trials?
The Wegovy results were measured with a diet and activity program in every group, placebo included. In most of its trials, everyone was told to eat about 500 kcal a day less than they needed and was counseled to be active for at least 150 minutes a week, from the first dose to the end.2
The trial with intensive lifestyle therapy went further: eight weeks on 1,000 to 1,200 kcal a day, then 60 weeks on 1,200 to 1,800 kcal a day, with physical activity rising from 100 to 200 minutes a week.2 The label's indication reflects this: Wegovy is approved in combination with a reduced-calorie diet and increased physical activity, and Ozempic as an adjunct to diet and exercise.1,2
What would those results look like at my weight?
The calculator turns each trial's average into a share of the average starting weight and applies it to yours. The Ozempic shares are our division of the label's kilograms; the Wegovy share is the label's own percentage.
Log your weight each week and see your own line next to these averages.
Open the appFour separate trials: different lengths, and people with type 2 diabetes for Ozempic against people with obesity or overweight for Wegovy. The bars show what each trial found. They do not show what switching from one product to the other would do.
Three things separate the Ozempic rows from the Wegovy row, and dose is only one of them. The Wegovy trial ran more than twice as long. Its participants were enrolled for obesity or overweight, not for diabetes. And its dose was higher. The label trials cannot say how much each of the three contributes.
Does the higher dose bring more side effects?
The labels' tables suggest so. Stomach and gut reactions are the most common ones for both products, and they were reported much more often in the Wegovy trials, at 2.4 mg, than in the Ozempic trials, at 0.5 mg and 1 mg.1,2
The placebo rates differ between the two sets of trials too, 6.1% against 16% for nausea, so each product should be compared with its own placebo.
Nausea was reported by 44% of people on Wegovy 2.4 mg, against 16% on placebo, and by 20.3% on Ozempic 1 mg, against 6.1% on placebo. In the Wegovy trials, 6.8% stopped treatment because of adverse reactions, against 3.2% on placebo. In the Ozempic trials, 3.1% on 0.5 mg and 3.8% on 1 mg stopped because of stomach and gut reactions, against 0.4%.1,2
What does 7.2 mg add?
The Wegovy label has a separate table for its highest dose, from trials that compared 7.2 mg with 2.4 mg and placebo. Three reactions stand out.2
| Reaction | Placebo | Wegovy 2.4 mg | Wegovy 7.2 mg |
|---|---|---|---|
| Nausea | 13% | 35% | 39% |
| Vomiting | 6% | 16% | 22% |
| Dysesthesia, an abnormal skin sensation | 0% | 6% | 22% |
Wegovy prescribing information, Table 4.2
In those trials 5% of people on 7.2 mg and 5% on 2.4 mg stopped treatment because of adverse reactions, against 2% on placebo.2
Beyond the stomach
The Wegovy table for 2.4 mg lists several reactions outside the gut that were more frequent than on placebo: headache in 14% against 10%, fatigue in 11% against 5%, dizziness in 8% against 4% and hair loss in 3% against 1%.2 The Ozempic label reports fatigue, a changed sense of taste and dizziness in more than 0.4% each, a rise in heart rate of 2 to 3 beats a minute, and gallstones in 1.5% of people on 0.5 mg and 0.4% on 1 mg.1
Less common reactions on Wegovy 2.4 mg
The Wegovy table runs further down than the five reactions in the chart. Each of these was reported more often than on placebo in the weight-reduction trials.2
| Reaction | Placebo | Wegovy 2.4 mg |
|---|---|---|
| Indigestion | 3% | 9% |
| Bloating | 5% | 7% |
| Belching | under 1% | 7% |
| Flatulence | 4% | 6% |
| Reflux | 3% | 5% |
| Gastritis | 1% | 4% |
Wegovy prescribing information, Table 3.2
Low blood sugar with insulin
The Ozempic label reports what happens when the drug is added to basal insulin. Over 30 weeks, low blood sugar with symptoms, at 70 mg/dL or below, was reported by 16.7% on 0.5 mg and 29.8% on 1 mg, against 15.2% on placebo, and severe episodes by 1.5% on 1 mg.1 Both labels say the risk may be lowered by reducing the dose of the insulin or the sulfonylurea.1,2
Both labels explain the slow ladder the same way: it is there to reduce these reactions. Wegovy's adds that if a dose is not tolerated during the increases, the next step can be delayed by four weeks.2
Which has evidence for the heart, kidneys and liver?
Both have a cardiovascular indication, for different people.1,2
| Outcome trial in the label | Who | Result |
|---|---|---|
| Ozempic, cardiovascular | Type 2 diabetes at high cardiovascular risk | Events in 6.6%, against 8.9% on placebo |
| Ozempic 1 mg, kidney | Type 2 diabetes with chronic kidney disease | Kidney outcome in 18.7%, against 23.2% on placebo |
| Wegovy 2.4 mg, cardiovascular | 17,604 adults with cardiovascular disease and obesity or overweight, without diabetes | Risk of a first event 20% lower than on placebo |
Hazard ratios: 0.74 for the Ozempic cardiovascular trial, 0.76 for the kidney trial, 0.80 for the Wegovy trial.1,2
The trials behind these rows differ in size and length. Ozempic's cardiovascular trial followed 3,297 people for a median of 2.1 years, and its kidney trial 3,533 people. Wegovy's cardiovascular trial followed 17,604 people for a median of 41.8 months, and by its end 31% of those on Wegovy and 27% of those on placebo had permanently stopped the study drug.1,2
Wegovy's liver indication rests on a trial of 800 adults with MASH and stage 2 or 3 fibrosis, assigned to 2.4 mg or placebo, with liver biopsies at 72 weeks.2
Only Ozempic has a kidney indication, and only Wegovy has one for the liver: noncirrhotic MASH with moderate to advanced fibrosis, approved under the accelerated pathway on the basis of improvement in the liver, with a confirmatory trial still required.2
Which warnings do they share?
Nearly all of them, since the drug is the same. Both labels carry the boxed warning about thyroid C-cell tumors seen in rodents, and both list pancreatitis, gallbladder disease, low blood sugar with insulin or a sulfonylurea, acute kidney injury from dehydration, severe stomach and gut reactions, allergic reactions, complications of diabetic retinopathy, and aspiration during general anesthesia or deep sedation.1,2 The Wegovy label adds a section on heart rate increase.2
Both give the same advice on pregnancy: stop at least 2 months before a planned pregnancy, because the drug takes that long to leave the body.1,2 The Ozempic label recommends no dose adjustment for kidney or liver impairment, and the Wegovy label reports that neither changes the drug's level in a way that matters clinically.
Do they behave differently in the body?
No. The half-life is about one week in both labels and exposure rises in proportion to the dose; the Ozempic label puts the time to a steady level at 4 to 5 weeks of weekly doses.1,2 A 2 mg dose of Ozempic and a 2.4 mg dose of Wegovy differ by a fifth in the amount injected and in nothing else about the molecule.
The dose and the level move together. The Wegovy label gives an average steady concentration of about 75 nmol/L on 2.4 mg and about 230 nmol/L on 7.2 mg: three times the dose, three times the level. The Ozempic label gives about 65 ng/mL on 0.5 mg and 123 ng/mL on 1 mg.1,2
Both labels allow the injection in the abdomen, the thigh or the upper arm, at any time of day, with or without meals.1,2 After the last dose, semaglutide stays in the circulation for about 5 weeks by the Ozempic label and about 5 to 7 weeks by the Wegovy label, which covers higher doses.1,2 The page on the week between shots shows the weekly curve.
What about the Wegovy tablet?
Wegovy also comes as a tablet taken once a day, which Ozempic's injection label does not have. The tablet goes from 1.5 mg to 4 mg, 9 mg and 25 mg, a month at each step. It is taken in the morning on an empty stomach with up to 4 ounces of water, swallowed whole, with a wait of at least 30 minutes before food, other drinks or other oral medicines.2
At NovoCare's self-pay prices the tablet costs $149 a month at 1.5 mg, $199 at 4 mg and $299 at 9 mg and 25 mg.4 The label says the 25 mg tablet is predicted to give concentrations comparable to the 2.4 mg injection, with more variation from person to person.2
Can either be used under 18?
Wegovy can, for weight reduction from age 12 in children with obesity. The label bases this on a 68-week placebo-controlled trial in 201 patients aged 12 and older whose BMI was at or above the 95th percentile for their age and sex, together with the adult trials.2 Ozempic's safety and efficacy have not been established in pediatric patients.1
What does each cost?
The list prices differ: $1,027.51 for an Ozempic pen and $1,349.02 for a Wegovy package. What people pay is closer together. With commercial insurance that covers the product, Novo Nordisk's savings offer brings either to as little as $25, taking off up to $100 a month. Without coverage, both start at $199 a month for the first two fills for new patients and then cost $349 a month, with a higher price for the top dose of each: $499 for Ozempic 2 mg and $399 for Wegovy 7.2 mg.3,4
Log each fill and what it cost, and the app adds up your year.
Open the appThirteen four-week fills make a year. Self-pay figures include the new-patient offer of $199 for each of the first two fills, which runs through December 31, 2026. Ozempic 2 mg is priced from the fourth fill and Wegovy 7.2 mg from the sixth, the earliest each label allows.
| Self-pay, 13 fills | Total |
|---|---|
| Ozempic, up to 1 mg | $4,237 |
| Wegovy, up to 2.4 mg | $4,237 |
| Wegovy, 7.2 mg from the sixth fill | $4,637 |
| Ozempic, 2 mg from the fourth fill | $5,737 |
Our arithmetic from the published prices.3,4
At list price the two are further apart: thirteen Ozempic pens come to $13,358 a year and thirteen Wegovy packages to $17,537. Novo Nordisk notes on both price pages that most people with health insurance do not pay the list price, and that what a person pays depends on the plan.3,4
The savings offers exclude people on government insurance. For Medicare, Novo Nordisk describes a separate federal program for Wegovy at $50 a month from July 2026 to December 2027.4 The Wegovy cost page has the pen, the pill and the Medicare program in detail.
How many people stay on semaglutide?
For the weight-loss use, more than before. In an analysis of health plan members without diabetes, 33.2% of those who started semaglutide in 2021 were still on treatment a year later, and 58.6% of those who started in the first half of 2024. The authors, who work for the company that paid for the analysis, point to the end of the shortages as one likely reason.6 The page on why people stop has the reasons people give, with cost first.
What if a dose is late?
The two labels word the rule differently and it comes to nearly the same thing. Ozempic: take a missed dose within 5 days, and after that skip it. Wegovy: take it if the next scheduled dose is more than 2 days away, and skip it if not.1,2
The curve is a model built on the label's half-life of about one week, for a settled dose. It is not a blood test.
Wegovy's label goes one step further for longer gaps. After two or more missed doses in a row it says to restart the dose increases at a lower dose, to reduce stomach and gut reactions.2 Ozempic's label has no such rule. Both allow the weekly day to be changed if at least 2 days separate the two doses.1,2
How do the pens differ?
An Ozempic pen holds several weekly doses: one pen for 0.25 mg and 0.5 mg, one for 1 mg and one for 2 mg. A Wegovy pen in its usual form holds a single dose and is used once; a box has four. The current Wegovy label also lists a pen with four 2.4 mg doses, and both labels now list single-dose syringes.1,2
After its first use an Ozempic pen can be kept for 56 days, at room temperature or in a refrigerator.1
Can I switch between them?
Neither label describes a switch from Ozempic to Wegovy or back. They contain the same drug, and the Wegovy label says not to use the two together.2 A change from one to the other is a new prescription, and the dose to continue on is the prescriber's decision. The doses overlap at 0.25 mg, 0.5 mg and 1 mg and differ above that.
The Wegovy label does describe one switch within the product: from the 2.4 mg injection to the 25 mg tablet, starting the tablet one week after the last injection, and from the tablet to the injection the day after the last tablet.2
Short answers to common questions
Is Wegovy just a higher dose of Ozempic?
It is the same drug at higher doses, with different approved uses. Ozempic stops at 2 mg; Wegovy's usual maintenance dose is 2.4 mg and its label allows 7.2 mg.
Can Ozempic be used for weight loss?
It is not approved for it. Its three uses in the label are all in adults with type 2 diabetes. In its trials people lost 3.8 to 6.4 kg on average, depending on the dose.
Which causes more weight loss?
The products have not been compared directly. In its own 68-week trial, Wegovy 2.4 mg produced an average loss of 14.9% in people with obesity or overweight. In Ozempic's trials in people with diabetes, the average loss was 3.8 to 6.4 kg over 30 to 40 weeks.
Which is cheaper?
Self-pay, both cost $349 a month at Novo Nordisk's prices for most doses. The top dose of Ozempic, 2 mg, is $499, and the top dose of Wegovy, 7.2 mg, is $399. With commercial coverage either can cost as little as $25.
Can I take both?
No. The Wegovy label says it should not be used with other semaglutide products or with any other GLP-1 receptor agonist.
Do they have the same side effects?
The same kinds, mostly in the stomach and gut. They were reported more often in the Wegovy trials, at 2.4 mg, than in the Ozempic trials at 0.5 mg and 1 mg.
Is the missed-dose rule the same?
Nearly. Ozempic allows a late dose up to 5 days after it was due. Wegovy allows it while the next dose is more than 2 days away, and tells people who miss two or more doses in a row to restart at a lower dose.
I have type 2 diabetes and obesity. Which label applies?
Both can. Ozempic is approved for blood sugar control in type 2 diabetes, and Wegovy for weight reduction whether or not a person has diabetes. The Wegovy label asks for blood sugar to be monitored before and during treatment in people with diabetes.
Is there a pill version?
Of Wegovy, yes: a once-daily tablet that goes from 1.5 mg to 25 mg. It is taken on an empty stomach with a little water, 30 minutes before anything else.
Do I need to stop either before pregnancy?
Both labels say to stop at least 2 months before a planned pregnancy.
Does Wegovy work as well in people with diabetes?
Less well on weight. In the label's trials, 2.4 mg produced an average loss of 9.6% over 68 weeks in people with type 2 diabetes, against 14.9% in the main trial.
Is 2.4 mg of Wegovy much more than 2 mg of Ozempic?
It is 20% more of the same drug. The two doses have not been compared in a trial.
Can teenagers take them?
Wegovy is approved for weight reduction from age 12 in children with obesity. Ozempic has not been established as safe and effective in pediatric patients.
Which one lowers blood sugar?
Both lower it, because the drug is the same, but only Ozempic is approved for blood sugar control. In its trials HbA1c fell 1.4 to 2.1 points depending on the dose.
Is Ozempic 2 mg the same as Wegovy 2.4 mg?
It is the same drug at a slightly lower dose, under a label for diabetes. The two have not been compared in a trial, and Ozempic 2 mg is not approved for weight reduction.
If I switch from Ozempic to Wegovy, do I start again at 0.25 mg?
Neither label says. Both start new patients at 0.25 mg to reduce stomach and gut reactions, and the doses match at 0.25, 0.5 and 1 mg. The dose to continue on is the prescriber's decision.
How long does semaglutide stay in the body?
Its half-life is about one week. The Ozempic label says it stays in the circulation for about 5 weeks after the last dose, and the Wegovy label, which covers higher doses, about 5 to 7 weeks.
Do I inject them the same way?
Yes: once a week, under the skin of the abdomen, thigh or upper arm, at any time of day, with or without meals.
How the calculators work
The calendar places each label's steps at 4-week intervals from the date you enter. The weight calculator multiplies your weight by each trial's average loss as a share of starting weight: 4.2%, 4.9% and 6.4% for Ozempic 0.5, 1 and 2 mg, which we worked out from the label's kilograms and average starting weights, and 14.9% and 9.6% for Wegovy 2.4 mg in its main trial and its trial in type 2 diabetes, which the label states.
The cost calculator adds 13 four-week fills at the prices Novo Nordisk published on November 20, 2026. The late-dose curve comes from our level model: one compartment, a half-life of 7 days and a peak 2 days after the injection.
Sources
- OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 1, 2, 3, 6.1, 8.4, 12.3, 14 and 16. accessdata.fda.gov
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 1, 2, 3, 6.1, 12.3 and 14. accessdata.fda.gov
- Novo Nordisk. Ozempic cost and insurance coverage, and NovoCare: explaining list price. Read November 20, 2026. ozempic.com
- Novo Nordisk. NovoCare: Price your Wegovy, and Save on Wegovy. Read November 20, 2026. novocare.com
- Ladebo L, Ernst MT, Mailhac A, Dirksen C, Bojsen-Møller KN, Pottegård A. Real-world use of semaglutide for weight management: patient characteristics and dose titration. A Danish cohort study. Diabetes Care 2024;47:1834-1837. doi:10.2337/dc24-1082
- Marshall LZ, Gleason PP, Friedlander N, Farley J, Urick BY. Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists. J Manag Care Spec Pharm 2026;32:281-291. doi:10.18553/jmcp.2026.32.3.281
Related analyses
Ozempic vs Zepbound: two drugs, two labels, and the trials that compared them
Wegovy vs Mounjaro: two drugs, two labels, and the trials that compared them
Mounjaro vs Zepbound: the same drug under two labels, compared by use, results and price
Switching from Wegovy to Zepbound: the starting dose, the timing, and what the evidence covers
Log your doses and weight, whichever name is on the box.
Open Dose Insider